Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 14/20 | 0.69 |
| ▸ | DYRK2 | Q92630 | 8/20 | 0.69 |
| ▸ | DYRK1B | Q9Y463 | 7/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.56 |
| ▸ | CDK2 | P24941 | 6/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.56 |
| ▸ | DYRK3 | O43781 | 6/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.52 |
| ▸ | CDK9 | P50750 | 4/20 | 0.52 |
| ▸ | PIM1 | P11309 | 3/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29436156 | 0.85 | DYRK1A (0.73) | DYRK1ADYRK2DYRK1BCCNA2CDK2 | |
| SCHEMBL102330 | 0.85 | DYRK1A (0.73) | DYRK1ADYRK2DYRK1BCCNA2CDK2 | |
| SCHEMBL3043884 | 0.82 | FYN (0.67) | DYRK1ADYRK2DYRK1BCCNA2CDK2 | |
| SCHEMBL14765143 | 0.82 | DYRK1A (1.00) | DYRK1ADYRK2DYRK1BCCNA2CDK2 | |
| SCHEMBL14373190 | 0.82 | DYRK1A (0.73) | DYRK1ADYRK2DYRK1BCCNA2CDK2 | |
| SCHEMBL102796 | 0.80 | DYRK1A (0.71) | DYRK1ADYRK2DYRK1BCCNA2CDK2 | |
| SCHEMBL3046666 | 0.80 | DYRK1A (0.59) | DYRK1ADYRK2DYRK1BCCNA2CDK2 | |
| SCHEMBL15288602 | 0.79 | DYRK1A (0.70) | DYRK1ADYRK2DYRK1BCCNA2CDK2 | |
| SCHEMBL136464 | 0.78 | DYRK1A (0.51) | DYRK1ADYRK2DYRK1BCCNA2CDK2 | |
| SCHEMBL102386 | 0.78 | DYRK1A (0.51) | DYRK1ADYRK2DYRK1BCCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086979-B1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS INC (US) | 2015-06-03 | — | — | EP | disclosed |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20100227861-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | disclosed |
| US-7750007-B2 | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors | SUPERGEN, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| WO-2008058126-A2 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUPERGEN, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058997-A1 | IMIDAZO[1,2-B]PYRIDAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 184/4885DYRK2 199/4885DYRK1B 185/4885 |
| US-20080261988-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 221/4885DYRK2 229/4885DYRK1B 235/4885 |
| US-20100227861-A1 | IMIDAZO[1,2-beta]PYRIDAZINE AND PYRAZOLO[1,5-alpha]PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | DYRK1A 221/4885DYRK2 229/4885DYRK1B 235/4885 |
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | LCK, ZAP70, FYN | DYRK1A 363/4885DYRK2 350/4885DYRK1B 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.